Targeting BRAF for patients with melanoma.

PubWeight™: 1.56‹?› | Rank: Top 4%

🔗 View Article (PMC 3049553)

Published in Br J Cancer on December 07, 2010

Authors

H-T Arkenau1, R Kefford, G V Long

Author Affiliations

1: Sarah Cannon Research UK, 93 Harley Street, London W1G 6AD, UK. tobias.arkenau@sarahcannonresearch.co.uk

Associated clinical trials:

A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3) | NCT01006980

Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212 | NCT01072175

A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma | NCT00949702

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor | NCT01037127

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors | NCT00880321

Study of XL281 in Adults With Solid Tumors | NCT00451880

Articles citing this

Evolution of the cancer genome. Nat Rev Genet (2012) 3.24

Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets (2012) 2.42

Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res (2011) 2.42

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res (2012) 1.90

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med (2014) 1.59

ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors. Biochim Biophys Acta (2012) 1.58

Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils. EMBO Mol Med (2011) 1.52

Clonal evolution in hematological malignancies and therapeutic implications. Leukemia (2013) 1.50

Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int (2015) 1.25

Dabrafenib and its potential for the treatment of metastatic melanoma. Drug Des Devel Ther (2012) 1.16

The combinatorial complexity of cancer precision medicine. Oncoscience (2014) 1.16

RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy. Dermatol Res Pract (2011) 1.15

Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab Invest (2011) 1.07

Oncogenic BRAF induces chronic ER stress condition resulting in increased basal autophagy and apoptotic resistance of cutaneous melanoma. Cell Death Differ (2014) 1.05

Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin Cancer Res (2012) 1.04

Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene (2013) 1.03

Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF. Front Oncol (2013) 1.02

Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing. Expert Rev Mol Diagn (2012) 0.97

Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors. Transl Oncol (2012) 0.95

BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications. Oncotarget (2014) 0.92

Nodal expression and detection in cancer: experience and challenges. Cancer Res (2012) 0.92

The evolution of S100B inhibitors for the treatment of malignant melanoma. Future Med Chem (2013) 0.91

Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Biosci Rep (2012) 0.90

What is new in the treatment of advanced melanoma? State of the art. Contemp Oncol (Pozn) (2012) 0.88

Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. Sci Rep (2015) 0.87

Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. Biochem Pharmacol (2012) 0.86

Spontaneous splenic rupture in patient with metastatic melanoma treated with vemurafenib. World J Surg Oncol (2012) 0.84

The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. Ther Adv Med Oncol (2012) 0.82

RAF265, a dual BRAF and VEGFR2 inhibitor, prevents osteoclast formation and resorption. Therapeutic implications. Invest New Drugs (2012) 0.80

Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations. Oncoscience (2015) 0.80

The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy. Acta Pharm Sin B (2014) 0.79

Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. PLoS One (2013) 0.78

Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice. PLoS One (2015) 0.77

Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf. Biochem J (2015) 0.77

KB-Rank: efficient protein structure and functional annotation identification via text query. J Struct Funct Genomics (2012) 0.77

Good clinical and radiological response to BRAF inhibitor in patient with metastatic thin melanoma. BMJ Case Rep (2012) 0.76

Articles cited by this

Mutations of the BRAF gene in human cancer. Nature (2002) 65.42

Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med (2010) 36.57

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell (2010) 17.48

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature (2010) 17.31

Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26

The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc Hum Genet (2008) 16.09

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature (2010) 15.63

Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81

MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res (2008) 6.05

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer (2006) 4.93

Cutaneous melanoma. Lancet (2005) 3.94

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol (2004) 3.80

B-RAF is a therapeutic target in melanoma. Oncogene (2004) 3.61

Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog (2004) 3.02

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer (2010) 2.83

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol (2005) 2.36

The cardiofaciocutaneous syndrome. J Med Genet (2006) 2.32

Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res (2008) 2.18

Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res (2004) 2.05

Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res (2009) 1.96

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer (2005) 1.89

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther (2008) 1.86

Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site. Mol Oncol (2007) 1.79

Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev (2007) 1.76

BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am (2009) 1.74

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol (2008) 1.71

B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One (2007) 1.65

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol (2008) 1.35

Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem (2003) 1.33

Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol (2006) 1.25

New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs). Curr Top Microbiol Immunol (2010) 1.14

Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. Mol Cancer Ther (2006) 1.10

Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res (2010) 1.08

BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res (2006) 1.02

The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel. Anticancer Res (2008) 0.95

Articles by these authors

Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer (1993) 1.64

Sequence and evolution of the human T-cell antigen receptor beta-chain genes. Proc Natl Acad Sci U S A (1985) 1.50

Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy. Lancet (1989) 1.47

Health-care interpreters and cancer. Med J Aust (1989) 1.39

Pulmonary toxicity associated with bleomycin. Med J Aust (1994) 1.39

Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol (2012) 1.33

Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus. Oncogene (1992) 1.20

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma. Br J Cancer (2013) 1.08

Focal encephalopathy after cisplatin therapy. Med J Aust (1989) 1.02

Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol (1987) 0.97

Meeting report from the Society for Melanoma Research 2012 Congress, Hollywood, California. Pigment Cell Melanoma Res (2013) 0.95

O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. Br J Cancer (2009) 0.95

A randomized trial of cisplatin versus cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol (1989) 0.93

Solution conformation of the antitumor drug streptonigrin. J Med Chem (1993) 0.88

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Cell Death Dis (2013) 0.85

Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol (2014) 0.77

Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and infusional vincristine, ifosfamide and epirubicin. Aust N Z J Med (1998) 0.76

Paraneoplastic myelopathy at diagnosis in a patient with pathologic stage 1A Hodgkin disease. Cancer (1992) 0.76

Evaluation of a school health program directed to children with history of high absence. Am J Public Health (1975) 0.75

Epirubicin: a phase II study in recurrent small-cell lung cancer. Cancer Chemother Pharmacol (1991) 0.75

Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Br J Dermatol (2013) 0.75

A phase II trial of oral 4'demethoxydaunorubicin (DMDR) in inoperable non small cell lung cancer. Invest New Drugs (1988) 0.75

The use of L-dopa and carbidopa in metastatic malignant melanoma. J Invest Dermatol (1991) 0.75

A novel model for metastasis suppression involving regulation of nuclear precursor messenger-RNA stability. Int J Oncol (1995) 0.75

Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. Eur J Cancer (1995) 0.75

Non-coexpression of collagenase and transin in malignant epithelial cells. Int J Oncol (1997) 0.75

Etoposide, carboplatin, cyclophosphamide and vincristine in previously untreated patients with small-cell lung cancer. Cancer Chemother Pharmacol (1990) 0.75

Dual sequential non-cross-resistant chemotherapy for advanced stage squamous cell carcinoma of the cervix. Gynecol Oncol (1992) 0.75

Doctors, nuclear war, and a town like Alice. Med War (1986) 0.75

Cancer in the family: risks and management. Med J Aust (2000) 0.75

Bone metastases in hypernephroma. Frequency of scapular involvement. Cancer (1989) 0.75

Chemotherapeutic induced fascial oedema. Ann Rheum Dis (2005) 0.75